UGT2B4 Antibody

What is UGT2B4 and what role does it play in human metabolism?

UGT2B4 (UDP Glucuronosyltransferase Family 2 Member B4) is an enzyme that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either urine or bile . This enzyme plays a critical role in:

• Detoxification of bile acids, steroids, and xenobiotics

• Elimination of potentially toxic compounds from the body

• Metabolism of endogenous estrogen hormones including estradiol and estriol

• 6 alpha-hydroxyglucuronidation of hyodeoxycholic acid (HDCA)

During cholestasis, UGT2B4 works in concert with SULT2A1 (another bile acid-conjugating enzyme) to prevent the accumulation of toxic bile acids .

UGT2B4 contains several crucial structural features:

• A signal peptide at the N-terminus

• A key aromatic amino acid residue at position 33 (phenylalanine) that is critical for substrate specificity and catalytic activity

• An active site involved in glucuronidation

• A transmembrane domain anchoring it to the endoplasmic reticulum membrane

Studies have shown that the presence of an aromatic residue at position 33 is particularly important for the activity and substrate specificity of both UGT2B4 and its related isoform UGT2B7. Substitution of phenylalanine 33 by leucine in UGT2B4 suppresses activity towards HDCA and impairs glucuronidation of several substrates including 4-hydroxyestrone and 17-epiestriol .

How should I optimize Western blot protocols for UGT2B4 detection?

For optimal Western blot detection of UGT2B4:

• Sample preparation:

  • Prepare cell lysates using RIPA buffer with protease inhibitors

  • Expected molecular weight of UGT2B4 is approximately 528 kDa

• Antibody selection and dilution:

  • For polyclonal antibodies: Use 1:750 dilution as a starting point (can be optimized)

  • Secondary antibody recommendation: HRP-conjugated goat anti-rabbit IgG (1:20,000)

• Detection and visualization:

  • Use enhanced chemiluminescence for protein detection

  • For semi-quantitative analysis, use β-actin (1:30,000-1:40,000 dilution) as loading control

Control experiments should include known UGT2B4-expressing tissues (liver) and negative controls (tissues known to lack UGT2B4 expression).

What are the optimal conditions for immunohistochemical detection of UGT2B4 in tissue samples?

For successful IHC detection of UGT2B4:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded tissues

  • Perform antigen retrieval (citrate buffer pH 6.0 is recommended)

• Antibody incubation:

  • Recommended dilution range for IHC: 1:30-1:150

  • Incubate at 4°C overnight for optimal results

• Detection system:

  • Use polymer-based detection systems for enhanced sensitivity

  • Include appropriate positive controls (liver tissue)

  • Use isotype controls to verify specificity

For dual staining applications, ensure the secondary antibodies don't cross-react and choose fluorophores with minimal spectral overlap if performing immunofluorescence.

How can I validate the specificity of a UGT2B4 antibody for my experimental system?

Multiple validation approaches should be employed:

• Western blot validation:

  • Verify single band at expected molecular weight

  • Test in tissues/cells with known UGT2B4 expression levels

  • Include UGT2B4 knockout/knockdown controls when possible

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide before application

  • Signal should be significantly reduced or abolished

• Cross-reactivity assessment:

  • Test against closely related UGT family members (particularly UGT2B7, which shares substrate specificity with UGT2B4)

  • Verify antibody doesn't recognize other UGT isoforms

• Recombinant protein testing:

  • Use recombinant UGT2B4 protein as a positive control

  • Test against recombinant related proteins to confirm specificity

How does the UGT2B4(D458E) polymorphism affect antibody binding and enzyme function?

The UGT2B4(D458E) polymorphism shows significant ethnic variation:

This polymorphism may affect:

• Antibody binding:

  • Antibodies targeting epitopes containing or near position 458 might show differential binding depending on the polymorphic variant

  • For research involving diverse ethnic populations, researchers should select antibodies that target conserved regions

• Functional consequences:

  • The polymorphism may alter substrate specificity or enzyme activity

  • When studying UGT2B4 function across different populations, consider genotyping subjects for this polymorphism

The ethnic differences in polymorphism distribution warrant careful consideration when designing studies involving multiple ethnic groups or when interpreting conflicting results from different population studies.

What approaches can be used to study the interaction between UGT2B4 and other enzymes in the bile acid detoxification pathway?

To study UGT2B4's interactions with other bile acid metabolism enzymes:

• Co-immunoprecipitation:

  • Use anti-UGT2B4 antibodies to pull down protein complexes

  • Probe for interacting partners like SULT2A1

  • Perform reciprocal IP to confirm interactions

• Proximity ligation assay:

  • Detect protein-protein interactions in situ

  • Particularly useful for membrane-bound proteins like UGT2B4

• Functional interaction studies:

  • Assess how modulation of UGT2B4 expression affects SULT2A1 and vice versa

  • Measure changes in bile acid profiles when one or both enzymes are inhibited

• Transcriptional coordination analysis:

  • Determine if UGT2B4 and SULT2A1 share regulatory mechanisms

  • Analyze promoter elements for common transcription factor binding sites

Research has shown that during cholestasis, UGT2B4 and SULT2A1 work coordinately, suggesting potential co-regulation mechanisms that could be therapeutic targets .

How can UGT2B4 antibodies be used to investigate the role of this enzyme in steroid hormone metabolism?

UGT2B4 antibodies can facilitate several approaches to study its role in steroid metabolism:

• Localization studies:

  • Use IHC/IF to map UGT2B4 expression in steroid-responsive tissues

  • Correlate expression with steroid receptor localization

• Expression regulation:

  • Study how hormonal stimuli affect UGT2B4 expression

  • Use WB to quantify protein levels in response to different hormones

• Metabolic profiling:

  • Immunodeplete UGT2B4 from microsomal preparations

  • Compare glucuronidation profiles of steroid substrates before and after depletion

• Structure-function studies:

  • Use antibodies recognizing different epitopes to investigate domain-specific functions

  • Combine with site-directed mutagenesis (e.g., F33L mutation) to correlate structure with catalytic activity

Research has demonstrated that UGT2B4 is active on polyhydroxylated estrogens such as estriol, 4-hydroxyestrone, and 2-hydroxyestriol, making it an important enzyme in estrogen metabolism .

What are common causes of non-specific binding when using UGT2B4 antibodies, and how can they be mitigated?

Common causes of non-specific binding include:

• Cross-reactivity with related UGT isoforms:

  • UGT2B4 shares sequence homology with other UGT2B family members

  • Solution: Use antibodies targeting unique epitopes of UGT2B4

  • Verify specificity using recombinant proteins of related UGTs

• Inadequate blocking:

  • Solution: Optimize blocking conditions (5% BSA often works better than milk for phospho-proteins)

  • Extend blocking time to 2 hours at room temperature

• Secondary antibody issues:

  • Solution: Use highly cross-adsorbed secondary antibodies

  • Include secondary-only controls in experiments

• Fixation artifacts in IHC/IF:

  • Solution: Optimize fixation protocols and antigen retrieval methods

  • Test multiple antibody clones that recognize different epitopes

For polyclonal antibodies like PA5-43384, which show 100% sequence homology to human UGT2B4 , thorough validation in your specific experimental system is particularly important to ensure specificity.

How should results be interpreted when there are discrepancies between protein detection methods (Western blot vs. IHC vs. IF) using UGT2B4 antibodies?

When faced with discrepancies between detection methods:

• Consider epitope accessibility:

  • Formalin fixation can mask epitopes in IHC that are accessible in WB

  • Native protein conformation in IF may differ from denatured forms in WB

  • Solution: Use alternative antibody clones targeting different epitopes

• Assess method sensitivity thresholds:

  • WB may detect low expression levels not visible by IHC

  • Solution: Use amplification methods for IHC/IF (tyramide signal amplification)

• Evaluate post-translational modifications:

  • Modifications may affect antibody binding differently across methods

  • Solution: Use phosphatase or glycosidase treatments to assess impact

• Consider heterogeneity in tissue samples:

  • UGT2B4 expression may vary within tissues, causing sampling discrepancies

  • Solution: Increase biological replicates and sampling areas

When publishing results, clearly report the specific antibody used, detection method, and observed discrepancies to facilitate proper interpretation by the scientific community.

How can UGT2B4 antibodies be employed in studying the enzyme's role in drug resistance mechanisms?

UGT2B4 antibodies can facilitate research into drug resistance through:

• Expression profiling in resistant cells:

  • Compare UGT2B4 levels between drug-sensitive and resistant cell lines

  • Correlate UGT2B4 expression with glucuronidation of specific drugs

• Mechanistic studies:

  • Use antibodies to identify regulatory proteins that interact with UGT2B4

  • Investigate how these interactions change in resistant cells

• In vivo relevance:

  • Perform IHC on patient samples pre- and post-treatment

  • Correlate UGT2B4 expression with treatment outcomes

• Therapeutic targeting:

  • Use antibodies to screen for compounds that modulate UGT2B4 activity

  • Test these compounds for ability to reverse drug resistance

Since UGT2B4 is involved in the metabolism of various xenobiotics , changes in its expression or activity may contribute to altered drug metabolism and resistance phenotypes.

What methodological approaches can be used to study the transcriptional regulation of UGT2B4 using antibodies against transcription factors?

To study UGT2B4 transcriptional regulation:

• Chromatin immunoprecipitation (ChIP):

  • Use antibodies against suspected transcription factors

  • Analyze binding to UGT2B4 promoter regions

  • Research has identified potential FXR (farnesoid X receptor) binding sites in the UGT2B4 promoter region

• Reporter assays with transcription factor modulation:

  • Use UGT2B4 promoter-reporter constructs (~2 Kb of the 5'-flanking region)

  • Combine with transcription factor overexpression or knockdown

  • Measure effects on promoter activity

• Protein-DNA interaction analysis:

  • Perform electrophoretic mobility shift assays using nuclear extracts

  • Use antibodies to identify specific transcription factors in the complexes

• Analysis of upstream regulatory elements:

  • Studies have identified distal regulatory elements between nucleotides -10090 and -10037 that affect UGT2B4 transcription

  • Generate deletion constructs to map critical regulatory regions

Research has shown that FXR activation or overexpression increases UGT2B4 promoter activity, though the relationship is complex as knocking down FXR does not significantly decrease UGT2B4 promoter activity .

How can mass spectrometry be combined with immunoprecipitation using UGT2B4 antibodies to advance our understanding of this enzyme's interactome?

Combining IP-MS with UGT2B4 antibodies enables:

• Comprehensive interactome mapping:

  • Immunoprecipitate UGT2B4 from relevant tissues/cells

  • Identify interacting proteins by mass spectrometry

  • Validate key interactions with reciprocal IP and co-localization studies

• Condition-specific interaction changes:

  • Compare interactomes under different physiological states

  • Assess how drug treatments affect UGT2B4 protein complexes

• Post-translational modification mapping:

  • Identify PTMs on immunoprecipitated UGT2B4

  • Determine how these modifications affect enzyme activity and interactions

• Structural insights:

  • Combine with hydrogen-deuterium exchange MS to probe structural changes

  • Assess how substrate binding affects protein conformation

This approach is particularly valuable for membrane-bound proteins like UGT2B4 that are challenging to study using traditional structural biology techniques, and can reveal unexpected regulatory mechanisms and potential therapeutic targets.

What statistical approaches are most appropriate for analyzing UGT2B4 expression data across different tissue samples or treatment conditions?

For rigorous analysis of UGT2B4 expression data:

• Normalization strategies:

  • For Western blot: Normalize to loading controls (β-actin, GAPDH)

  • For qRT-PCR: Use multiple reference genes for normalization

  • For IHC: Consider digital pathology quantification with normalization to tissue area

• Statistical tests for different experimental designs:

  • Two-group comparisons: Student's t-test or Mann-Whitney U test (non-parametric)

  • Multiple group comparisons: ANOVA with appropriate post-hoc tests

  • Correlation analyses: Pearson or Spearman correlation coefficients

• Sample size considerations:

  • Conduct power analysis based on expected effect sizes

  • For human studies, account for UGT2B4 polymorphism frequencies in the population

• Handling outliers:

  • Establish clear criteria for outlier identification

  • Consider robust statistical methods less sensitive to outliers

When analyzing ethnic differences in UGT2B4 polymorphisms, consider appropriate statistical tests for genetic association studies and correct for multiple testing when assessing multiple SNPs or phenotypes .

How can researchers effectively integrate UGT2B4 antibody-based data with other omics approaches to gain comprehensive insights into glucuronidation pathways?

Effective integration of antibody-based data with other omics approaches:

• Multi-omics correlation analysis:

  • Correlate protein expression (antibody-based) with mRNA levels (transcriptomics)

  • Integrate with metabolomics data on glucuronide metabolites

  • Use pathway analysis tools to identify regulatory networks

• Systems biology approaches:

  • Develop mathematical models of UGT2B4-mediated glucuronidation

  • Incorporate antibody-derived protein quantification data

  • Use models to predict effects of perturbations

• Integration with genetic data:

  • Correlate UGT2B4 protein levels with genotype data (UGT2B4 polymorphisms)

  • Assess if protein expression explains genotype-phenotype relationships

• Visualization and interpretation:

  • Use advanced visualization tools to integrate multiple data types

  • Apply machine learning approaches to identify patterns across datasets

This integrated approach can reveal unexpected regulatory relationships and compensatory mechanisms in glucuronidation pathways that might not be apparent from antibody-based studies alone.